Document is current

Article History

First Online: 10 August 2024

Disclosure

: Lauren E. Schleimer, Hannah L. Kalvin, Ryan J. Ellis, T. Peter Kingham, Kevin C. Soares, Michael I. D’Angelica, and William R. Jarnagin report no relevant conflicts of interest. Vinod P. Balachandran reports research funding from Genetech/Roche and is an inventor on patent applications related to antigen cross-reactivity and neoantigen quality modeling. Jeffrey Drebin reports employment and leadership at American Regent (spouse), and stock and other ownership interests in Alnylam, Arrowhead Pharmaceuticals and Ions Pharmaceuticals. Andrea Cercek reports stock ownership in Haystack Oncology; consulting/advisory roles at Bayer, Daiichi Sankyo/Astra Zeneca, G1 Therapeutics, GlaxoSmithKline, Incyte, Janssen, Merck, and Seagen; and research funding from GlaxoSmithKline, and Seagen. Ghassan K. Abou-Alfa reports consulting/advisory roles at Agios, Genentech-Roche, Eisai, Servier, Arcus (spouse), Alligator (spouse), Agenus (spouse), BioNTech (spouse), Ipsen (spouse), Merck (spouse), Moma Therapeutics (spouse), Novartis (spouse), Syros (spouse), Leap Therapeutics (spouse), Astellas (spouse), BMS (spouse), Fibrogen (spouse), Revolution Medicine (spouse), and Merus (spouse). Eileen M. O’Reilly reports consulting for Arcus, Alligator, Agenus, BioNTech, Ipsen, Merck, Moma Therapeutics, Novartis, Syros, Leap Therapeutics, Astellas, BMS, Fibrogen, Revolution Medicine and Merus, Agios (spouse), Genentech-Roche (spouse), Eisai (spouse) and Servier (spouse); and institutional research funding from Genentech/Roche, BioNTech, AstraZeneca, Arcus, Elicio, Parker Institute, Digestive Care, and Break Through Cancer. James J. Harding reports consulting/advisory roles in Adaptimmune, Bristol-Myers Squibb, CytomX Therapeutics, Eisai, Elevar Therapeutics, Exelixis, Hepion Pharmaceuticals, Imvax, Lilly, Medivir, Merck, QED Therapeutics, and Zymeworks; and institutional research funding from Boehringer Ingelheim, Bristol-Myers Squibb, Calithera Biosciences, Codiak Biosciences, Debiopharm Group, Genoscience Pharma, Incyte, Lilly, Loxo, Novartis, Pfizer, Polaris, Yiviva, and Zymeworks. Mithat Gönen reports travel, accommodations and expenses from Genentech. Alice C. Wei reports consulting roles at Histosonic and institutional research funding from Ipsen.